Clinical trials: Reduction in Pain
Sickle Cell Disease
A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease
The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease
- Trial name
- Hestia2 (NCT02482298)
- Testing
- Ticagrelor
- Where
- 20 sites in United States, Egypt and 6 more
- Volunteers
- 87 people
- Sponsor
- AstraZeneca
Breast Cancer With Metastatic Bone Disease
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
The aim of this prospective, randomized, open-label, multicentric clinical study is to assess the effícacy and tolerability of zoledronic acid 4 mg IV infused over 15 minutes every 4 weeks for a total of 6 infusions, in…
- Trial name
- NCT00172029
- Testing
- Zoledronic acid
- Where
- 7 sites in Turkey (Türkiye)
- Volunteers
- 116 people
- Sponsor
- Novartis
Myocardial Ischemia
ACT34-CMI -- Adult Autologous CD34+ Cells
The purpose of this study is to evaluate the efficacy and safety of intramyocardial injections of CLBS14 in patients with refractory chronic myocardial ischemia.
- Trial name
- NCT00300053
- Testing
- CLBS14 (low-dose), CLBS14 (high-dose)
- Where
- 26 sites in United States
- Volunteers
- 321 people
- Sponsor
- Lisata Therapeutics, Inc.
Refractory Angina Pectoris, Ischemic Heart Disease
Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve
The purpose of the study is to assess the feasibility of Cardiac Shock Wave Treatment in patients with anginal chest pain and evidence of abnormal myocardial perfusion under stress in the absence of significant stenoses of the…
- Conditions
- Refractory Angina Pectoris, Ischemic Heart Disease, Coronary Artery Disease
- Trial name
- NCT03438500
- Testing
- Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)
- Where
- Germany
- Sponsor
- Storz Medical AG
Endometriosis
Pilot Study on a Dietary Supplement With EndoGen™ as Adjunct Therapy in Women With Endometriosis
Current treatments for endometriosis, such as NSAIDs and hormone therapies, are meant for long-term use but often cause side effects, including stomach, liver, heart, and kidney issues; allergies; and hormonal problems like…
- Trial name
- NCT07228975
- Testing
- MetrioFen Gocce
- Where
- 7 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Endok s.r.l.
Percutaneous Coronary Intervention
Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)
Patients who is scheduled elective PCI are randomized to pitavastatin 4mg daily or without pitavastatin for 5 -7days before the procedure.
- Trial name
- NCT00786734
- Testing
- Pitavastatin
- Where
- South Korea
- Sponsor
- JW Pharmaceutical
Osteoarthritis Knee Pain
A Study of Duloxetine in Patients With Osteoarthritis Knee Pain
The primary purpose of this study is to determine if duloxetine 60 mg once daily (QD) reduces pain severity in patients with osteoarthritis (OA) knee pain compared with placebo.
- Trial name
- NCT00945945
- Testing
- Duloxetine (DLX)
- Where
- 26 sites in United States, Germany and 6 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Post-herpetic Neuralgia
Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)
This study was designed to characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN).
- Trial name
- EMPHENE (NCT03094195)
- Testing
- EMA401
- Where
- 58 sites in Australia, Austria and 17 more
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Peripheral Neuropathy, Pain
A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)
The purpose of the study is to assess efficacy and safety of a single treatment of Capsaicin 8% transdermal delivery system in reducing pain from damaged nerves (neuropathic pain) caused by diabetes.
- Trial name
- STEP (NCT01533428)
- Testing
- Capsaicin 8%
- Where
- 29 sites in United States
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Sickle Cell Disease
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
The purpose of this study is to compare the effect of ticagrelor vs placebo for the reduction of Vaso-Occlusive crises in paediatric patients with Sickle Cell Disease
- Trial name
- HESTIA5 (NCT04293172)
- Testing
- Brilinta
- Sponsor
- AstraZeneca
Atherosclerosis, Coronary Artery Disease
ARISE - Aggressive Reduction of Inflammation Stops Events
To assess the safety and efficacy of AGI-1067, as compared to placebo, in the treatment of vascular inflammation and atherosclerosis by assessing the reduction in cardiovascular events.
- Conditions
- Atherosclerosis, Coronary Artery Disease, Myocardial Infarction, Unstable Angina
- Trial name
- NCT00066898
- Testing
- AGI-1067
- Where
- 219 sites in United States, Canada and 2 more
- Volunteers
- 6,000 people
- Sponsor
- AtheroGenics
Postherpetic Neuralgia
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
The purpose of the study is to evaluate the efficacy of retigabine vs. placebo in reducing pain associated with post-herpetic neuralgia.
- Trial name
- NCT00612105
- Testing
- Retigabine
- Where
- 45 sites in United States, South Africa
- Volunteers
- 187 people
- Sponsor
- Bausch Health Americas, Inc.
Pain
Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain
The primary objective of this study is to assess the efficacy of ataciguat versus placebo in reducing pain intensity in patients with neuropathic pain.
- Trial name
- SERENEATI (NCT00799656)
- Testing
- ataciguat (HMR1766)
- Where
- 3 sites in Austria, Czechia and 1 more
- Volunteers
- 62 people
- Sponsor
- Sanofi
Osteoarthritis
Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint
The study is designed to evaluate the efficacy, safety and tolerability of OLP-1002 Subcutaneous (SC) injections for reducing moderate to severe pain due to osteoarthritis in a hip and/or knee joint.
- Trial name
- NCT05216341
- Testing
- OLP-1002
- Where
- 7 sites in Australia
- Volunteers
- 134 people
- Sponsor
- OliPass Corporation
Knee Osteoarthritis, Knee Pain Chronic
Evaluation of NMES for Reducing Pain and Improving Functional Outcomes in Knee OA Patients
The present prospective trial is designed to evaluate the efficacy of CyMedica Orthopedics e-vive™ system, a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES) for reducing pain and…
- Conditions
- Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- Trial name
- NMES (NCT03980964)
- Testing
- Active NMES
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CyMedica Orthopedics, Inc